BTIG Research Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research note issued to investors on Thursday,Benzinga reports. They currently have a $39.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 25.73% from the company’s current price.

A number of other analysts also recently weighed in on the company. Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. Guggenheim started coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective on the stock. Needham & Company LLC upped their target price on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Wedbush raised their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Wolfe Research initiated coverage on Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $39.83.

Stoke Therapeutics Stock Down 5.6%

STOK opened at $31.02 on Thursday. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $40.22. The company has a fifty day moving average of $32.61 and a 200-day moving average of $29.90. The stock has a market cap of $1.83 billion, a PE ratio of 46.30 and a beta of 1.07.

Insider Activity

In other news, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the transaction, the director owned 283,302 shares of the company’s stock, valued at $11,258,421.48. This represents a 10.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Arthur Tzianabos sold 4,355 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total value of $174,200.00. Following the completion of the sale, the insider owned 31,339 shares of the company’s stock, valued at approximately $1,253,560. This represents a 12.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,203 shares of company stock worth $1,517,541 in the last quarter. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 1.2% during the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after acquiring an additional 354 shares in the last quarter. Strs Ohio grew its position in Stoke Therapeutics by 9.4% in the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $222,000 after purchasing an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after purchasing an additional 658 shares during the period. Generali Investments Management Co LLC increased its stake in Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after purchasing an additional 718 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the 4th quarter valued at $26,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.